Navigation Links
Golden Seeds Invests In DxUpClose, Disruptive Technology That Performs An Antibiotic Sensitivity Test At The Patient's Bedside In Less Than An Hour
Date:8/15/2012

DALLAS, Aug. 15, 2012 /PRNewswire/ -- Golden Seeds has invested in a $1.0M Series A financing of DxUpClose. DxUpClose is developing an in-vitro antibiotic sensitivity test for use at point-of-care, designed to deliver results in less than an hour. The first target market is urinary tract infections. Physicians currently do not have real time tools to test antibiotics against bacteria so they have to guess or order expensive lab tests which take 24 to 48 hours for results. Without lab tests, 10% of the time the wrong antibiotic is prescribed. This causes $2.7 billion per year in unnecessary costs due to misdiagnosis and acerbates the growing antibiotic resistance problem. In less than an hour, this bedside test could reduce the guess work and give better results to millions of patients.

The product personalizes medicine by doing three things within one hour at the patient's bedside: list antibiotics proven to be effective against the bacteria, screen for deadly bacteria, and count bacteria present.  The electronic sensor is designed to withstand hot and cold shipping conditions, weigh less than 16 oz and run on batteries.   

"This funding will help us complete the development of the product, enhance sensitivity of the diagnostic, and achieve FDA's design verification milestone" said Cyndi Nickel, DxUpClose's CEO.

"DxUpClose will bring a state of the art diagnostic solution to sufferers of a very painful illness, reduce healthcare costs and assist doctors in providing the best healthcare to their patients", said Jan Norton, Managing Director, Golden Seeds, who co-led the financing and joins the company's board as an observer.

About DxUpClose
DxUpClose was founded in 2009 by Cyndi Nickel, former Hewlett Packard executive in cutting edge technologies.  She combines her business acumen with researchers, inventors and patents from both Texas A&M University and Texas State University to develop a state of the art solution by personalizing medicine to solve a common problem.

About Golden Seeds
Golden Seeds is an investment firm dedicated to delivering above market returns for investors through the empowerment of women entrepreneurs and the people who invest in them. Its angel network consisting of 250 men and women is the fourth largest in the US and was the third most active in terms of deals done in 2011.

CONTACT
Lou Peralta
888-629-6774 x561


'/>"/>
SOURCE Golden Seeds
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Golden Meditech Holdings Limited Announces 2011/ 2012 Annual Results
2. Sentry BioPharma Services Invests in Global Clinical Supply Services with -45C Freezer Expansion
3. Hanger clinicians honored with 2012 Tribeca Disruptive Innovation Award
4. Biotechnology Thought Leader, Dr. Abbie Celniker, Joins ImaginAb Board of Directors as Chairman
5. Global Chiral Technology Industry
6. Antibiotics and Biotechnology Take Center Stage at Food Dialogues Event
7. Elekta Technology at Work in 100 Percent of Americas Top Cancer Hospitals
8. Survey: Hospital Executives Nationwide Facing Operating Room Case Volume Increases, Seeking Greater Efficiency through Healthcare Information Technology (HIT)
9. Global Information Inc Offers Big Discounts on Market Forecasts for Surgical Sealants, Wound Closure Products, Spine Surgery Technology, and More
10. Leading Medical Technology Company Selects inContact to Transform Service Experience
11. Kam Aims Uses Cloud Technology to Bring Affordable Solution to Freestanding Ambulatory Surgery Centers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... Feb. 17, 2017   FormFast , the leader ... new partnership with Engage , one of the ... . FormFast will serve as the forms automation ... with MEDITECH .  FormFast is ... to complement and enhance the electronic health record. FormFast,s ...
(Date:2/17/2017)... 2017  Noble Capital Markets announced today that it ... EPIX ). The report was issued by ... PhD. ESSA Pharmaceuticals is a clinical stage ... (CRPC). Its lead compound EPI-506, is a small molecule ... the androgen receptor, thereby has potential to overcome some ...
(Date:2/16/2017)... -- DaVita Inc. (NYSE: DVA ) today announced ... Net income attributable to DaVita Inc. for ... million, or $0.80 per share and $880 million, or $4.29 ... to DaVita Inc. for the quarter and year ended December ... million, or $0.98 per share, and $789 million, or $3.85 ...
Breaking Medicine Technology:
(Date:2/17/2017)... ... February 17, 2017 , ... Like most hospitals across the ... in large part by the Hospital Readmission Reduction Program (HRRP), the return of a ... area for hospitals across the nation. While many providers are struggling to leverage limited ...
(Date:2/17/2017)... ... February 17, 2017 , ... The Mason Pasquin Agency, ... and business owners in and around the Hampton Roads metropolitan region, is joining ... forms of domestic violence. , There are multiple categories of domestic violence – ...
(Date:2/16/2017)... ... February 17, 2017 , ... ... over 10 years of research, development and clinical trials, the founder of Chigurupati ... a patented compound of FDA approved ingredients that when infused into alcohol, protect ...
(Date:2/16/2017)... ... February 17, 2017 , ... Teaching nursing care of vulnerable children is ... ACE.P (pediatrics) is being created with the support of the Hearst Foundations. An initiative ... ACE.P will address what has been identified as a critical gap in preparing the ...
(Date:2/16/2017)... ... February 16, 2017 , ... As a reflection ... patient care, NWH has achieved Magnet® recognition for the second time, ... 2017. The American Nurses Credentialing Center’s Magnet Recognition Program® distinguishes organizations that meet ...
Breaking Medicine News(10 mins):